The collection of updates brings a mixed view of the bio-tech company
Amgen. Amgen is slated to present at the 2025
JP Morgan Healthcare Conference and has witnessed increased interest from investment companies such as
Graypoint LLC and
Wealth Enhancement Advisory Services. Moreover,
Asher Bio has partnered with Amgen to test a ground-breaking
lung cancer combination therapy. The firm's financial performance indicates a rise in
dividend payouts. The company has undergone
financial growth , seen through
Q4 2024 earnings and
third-quarter 2024 financial results. Clinical trials are showcasing promising results for new therapies like
MariTide, an obesity treatment and
Uplizna for myasthenia gravis. However, there has been a downgrade based on Amgen's
obesity drug while the firm faces a lawsuit over allegedly concealing a
$10.7 billion tax bill. Overall, Amgen exhibits potential growth, research capabilities, and a strong position, balanced with challenges, giving investors a lot to contemplate.
Amgen AMGN News Analytics from Thu, 02 May 2024 07:00:00 GMT to Sat, 11 Jan 2025 09:45:17 GMT -
Rating 2
- Innovation 5
- Information 7
- Rumor 3
